NYSE American - Delayed Quote USD

Palatin Technologies, Inc. (PTN)

1.8200

+0.1000

(+5.81%)

At close: April 26 at 4:00 PM EDT

1.7600

-0.06

(-3.30%)

After hours: April 26 at 6:14 PM EDT

10 Micro-Cap Healthcare Stocks Insiders Are Buying

In this article, we will take a detailed look at the 10 Micro-Cap Healthcare Stocks Insiders Are Buying. For a quick overview of such stocks, read our article 5 Micro-Cap Healthcare Stocks Insiders Are Buying. Investors have always been interested in the connection between insider buying and stock returns. Over the past several years there’s been a huge influx […]

Insider Monkey 13 days ago

PTN
+5.81%
DOMH

FLGC
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study

A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.

Zacks 18 days ago

PTN
+5.81%
ANIP

LGNZZ
Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data

On Monday, Palatin Technologies Inc. (NYSE:PTN) announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 trial, which evaluated the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery. The company released the mixed topline data in February 2024. The presentation included MELODY-1 Phase 3 data results, which indicate that the Intent-to-Treat PL9643 treatment population demonstrated

Benzinga 19 days ago

PTN
+5.81%
$Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024$
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of topline results for its Phase 3 PL9643 MELODY-1 pivotal clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery (ASCRS).

PR Newswire 19 days ago

PTN
+5.81%
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced results for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).

PR Newswire last month

PTN
+5.81%
Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript

Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript February 15, 2024 Palatin Technologies, Inc. misses on earnings expectations. Reported EPS is $-0.56 EPS, expectations were $-0.43. Palatin Technologies, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome […]

Insider Monkey 2 months ago

PTN
+5.81%
Q2 2024 Palatin Technologies Inc Earnings Call

Q2 2024 Palatin Technologies Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

PTN
+5.81%
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal second quarter ended December 31, 2023.

PR Newswire 2 months ago

PTN
+5.81%
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before the open of the U.S. financial markets.

PR Newswire 2 months ago

PTN
+5.81%
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced database lock for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED).

PR Newswire 2 months ago

PTN
+5.81%
Palatin Announces Closing of $10 Million Registered Direct Offering

Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced registered direct offering of 1,831,503 shares of its common stock, at a purchase price of $5.46 per share of common stock. Palatin has also issued in a private placement warrants to purchase up to an aggregate of 1,831

PR Newswire 2 months ago

PTN
+5.81%
Palatin Announces $10 Million Registered Direct Offering

Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of 1,831,503 shares of its common stock, at a purchase price of $5.46 per share of common stock. Palatin has also agreed

PR Newswire 2 months ago

PTN
+5.81%
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?

Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks 2 months ago

RGEN

PTN
+5.81%
3 Penny Stocks to Buy to Unlock 2,500% Upside Potential

After four long years of volatility and economic uncertainty, there finally appears to be light at the end of the tunnel heading into 2024. As rates start coming down and monetary policy loosens, we could see significant tailwinds for beaten-down penny stocks primed for a rebound. Penny stocks tend to thrive when monetary policies favor economic expansion and easy money. However, the past few years have been the exact opposite, with quantitative tightening, balance sheet contraction, and restric

InvestorPlace 3 months ago

CLIR

PTN
+5.81%
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today provided a corporate update, highlighted the Company's key calendar year 2023 accomplishments and outlined its anticipated calendar year 2024 clinical development milestones.

PR Newswire 3 months ago

PTN
+5.81%
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

BRIDGEWATER, N.J., January 03, 2024--Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

Business Wire 3 months ago

PTN
+5.81%
Analysts Say 3 Stocks Have a Combined Upside of 3000%

Wall Street analysts can get a bit optimistic with their price targets. So when I see calls for triple-digit upside, I take them with a grain of salt. But the three stocks I’m profiling today have targets so high I had to do a double-take. Analysts forecast these stocks to soar around 2,800% from current levels if their ambitious projections materialize. Now, such returns are obviously on the highest end of probabilities – a lot would need to go right. However, analysts arrive at these targets f

InvestorPlace 4 months ago

PTN
+5.81%
LLAP-WS
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the sale of Vyleesi® to Cosette Pharmaceuticals, a US-based, speciality pharmaceutical company, for up to $171 million, consisting of an upfront purchase price of $12 million plus contingent, sales-based milestone payments of up to $159 million. Vyleesi is the first and only as-needed tr

PR Newswire 4 months ago

PTN
+5.81%
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") approving Palatin's plan (the "Plan") to come into compliance with the Exchange's continued listing standards under Section 1003(a)(i) and (ii) of the NYSE American Company Guide. Section 1003(a)(i) requires a list

PR Newswire 4 months ago

PTN
+5.81%
Palatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call Transcript

Palatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call Transcript November 14, 2023 Operator: Greetings. Welcome to Palatin’s First Quarter Fiscal Year 2024 Operating Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. Before […]

Insider Monkey 5 months ago

PTN
+5.81%

Performance Overview

Return	PTN	S&P 500
YTD	-54.27%	+6.92%
1-Year	-22.55%	+25.26%
3-Year	-87.87%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Palatin Technologies, Inc. (PTN)

10 Micro-Cap Healthcare Stocks Insiders Are Buying

Palatin (PTN) Up 15% on Results From Dry Eye Disease Study

Palatin Technologies Eyes Growing $6B Dry Eye Disease Market With Late-Stage Study Data

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript

Q2 2024 Palatin Technologies Inc Earnings Call

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024

Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Palatin Announces Closing of $10 Million Registered Direct Offering

Palatin Announces $10 Million Registered Direct Offering

Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?

3 Penny Stocks to Buy to Unlock 2,500% Upside Potential

Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

Analysts Say 3 Stocks Have a Combined Upside of 3000%

Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million

Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

Palatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call Transcript

Performance Overview